16 / 56
16
Scientific programme
Thursday, 20 April 2017
HT-06
Hot Topic Symposium
16:00–17:30
Ballroom BC
Next generation of longitudinal studies of ADHD
Chairs:
N. Rommelse, The Netherlands
HT-06-001 Methodological challenges in ADHD
longitudinal studies
M. Sibley, USA
HT-06-002 Predictors of adolescent-onset ADHD
A. Caye, Brazil
HT-06-003 Contribution of genetic risk variants to
ADHD trajectories in the general popu-
lation
L. Riglin, United Kingdom
HT-06-004 A 6-year follow-up of a large European
cohort of children with ADHD-combined
subtype: Outcome in late adolescence
and young adulthood
N. Rommelse, The Netherlands
HT-07
Hot Topic Symposium
16:00–17:30
East Meetingroom 11/12
Patient or pretender: Feigned ADHD and its detection
Chairs:
M. Musso, USA
O. Tucha, The Netherlands
HT-07-001 Introduction to the detection of feigned
adult adhd and approaches to the as-
sessment of credibility
O. Tucha, The Netherlands
HT-07-002 Common ADHD symptom scales and
their limitations
J. Suhr, USA
HT-07-003 Performance validity testing in detecting
feigned ADHD
A. B. M. Fuermaier, The Netherlands
HT-07-004 The utility of personality inventories
M. Musso, USA
HT-08
Hot Topic Symposium
16:00–17:30
East Meetingroom 8/15
ADHD and circadian rhythm disturbances
Chairs:
A. Coogan, Ireland
M. Antle, Canada
HT-08-001 Sleep and circadian regulation – from
normal to abnormal human behaviour
K. Wulff, United Kingdom
HT-08-003 How might circadian rhythm change
impact on ADHD symptoms?
A. Coogan, Ireland
HT-08-004 How does ADHD medications impact on
the circadian clock?
M. Antle, Canada
HT-09
Hot Topic Symposium
16:00–17:30
East Meetingroom 9
Biomarkers of ADHD
(Supported by the Verein zur Durchführung Neurowis
senschaftlicher Tagungen e.V., Germany, with an unre-
stricted grant)
Chairs:
J. Buitelaar, The Netherlands
M. Romanos, Germany
HT-09-001 Toward integrating levels of sub-phe-
notype analysis, brain, and genetics in
ADHD
J. T. Nigg, USA
HT-09-002 Chemosensoring processing
M. Romanos, Germany
HT-09-003 EEG and MRI markers – research and
FDA status
D. Brandeis, Switzerland
HT-09-004 Neural activation patterns during re-
sponse inhibition
J. Buitelaar, The Netherlands